会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • CD93 또는 이의 가용성 단편을 유효성분으로 함유하는 염증성 질환 진단용 마커
    • 用于诊断包含CD93或可溶性片段的炎症性疾病的标记
    • KR1020110060205A
    • 2011-06-08
    • KR1020090116723
    • 2009-11-30
    • 한국생명공학연구원
    • 박영우전재원정준구손명호최혜인김호연조미라장영순문지현
    • G01N33/53G01N33/68
    • PURPOSE: A marker containing CD93 or soluble fragment thereof for diagnosing inflammatory diseases is provided. CONSTITUTION: A marker for diagnosing inflammatory diseases contains CD93 or soluble fragment thereof as an active ingredient. The soluble fragment is ectodomain of CD93 which is released after cell culture. A kit for diagnosing inflammatory diseases contains an antibody which specifically binds to CD93 or soluble fragment thereof or aptamer. A method for detecting CD93 or the soluble fragment comprises: a step of coating a biological sample and proteins of a control group to a fixture; a step of adding the antibody for antigen-antibody binding reaction; a step of detecting the antigen-antibody binding reactant using a marker of secondary antibody conjugate and chromogenic substrate; and a step of comparing the biological sample and a control group.
    • 目的:提供含有CD93或其可溶性片段的标志物,用于诊断炎性疾病。 构成:用于诊断炎性疾病的标记物含有CD93或其可溶性片段作为活性成分。 可溶性片段是细胞培养后释放的CD93的胞外域。 用于诊断炎性疾病的试剂盒含有特异性结合CD93或其可溶性片段或适体的抗体。 检测CD93或可溶性片段的方法包括:将生物样品和对照组的蛋白质涂覆到固定装置上的步骤; 将抗体加入抗原 - 抗体结合反应的步骤; 使用二抗缀合物和显色底物的标记物检测抗原 - 抗体结合反应物的步骤; 以及比较生物样品和对照组的步骤。
    • 5. 发明公开
    • 메트립타아제-특이적인 인간 항체 및 그의 용도
    • 基因特异性全身人体抗体及其用途
    • KR1020130091132A
    • 2013-08-16
    • KR1020120012429
    • 2012-02-07
    • 한국생명공학연구원한국전자통신연구원
    • 박영우김동진박지현손명호이기세이유라성건용김완중박찬우아칠성양종헌정광효최요한장명희
    • C07K16/18C12N15/13A61K39/395A61P35/00
    • PURPOSE: Metriptase-specific human antibody is provided to be usefully used to diagnosis, prevention and treatment of cancer which is a disease related to the manifestation and be especially used as a kit for cancer diagnosis. CONSTITUTION: Human monoclonal antibody specific to matriptase protein or a fraction having immunological activity of the antibody comprises heavy chain complementarity determining regions (HCDR1) having an amino acid sequence of the sequence number 12, heavy chain that includes the heavy variable domain (V_H) which includes HCDR2 having an amino acid sequence of the sequence number 13 and HCDR3 having an amino acid sequence of the sequence number 14, light chain complementarity determining regions (HCDR1) having an amino acid sequence of the sequence number 16 and light chain having light variable domain (V_L) which includes LCDR2 having an amino acid sequence of the sequence number 17 and LCDR3 having an amino acid sequence of the sequence number 18.
    • 目的:提供Metriptase特异性人抗体用于诊断,预防和治疗癌症,这是一种与表现相关的疾病,特别用作癌症诊断的试剂盒。 构成:具有对matriptase蛋白质或具有抗体免疫活性的级分的人单克隆抗体包括具有序列号12的氨基酸序列的重链互补决定区(HCDR1),重链包括重链可变结构域(V_H),重链可变区 包括具有序列号13的氨基酸序列的HCDR2和具有序列号14的氨基酸序列的HCDR3,具有序列号16的氨基酸序列的轻链互补决定区(HCDR1)和具有光可变结构域的轻链 (V_L),其包括具有序列号17的氨基酸序列的LCDR2和具有序列号18的氨基酸序列的LCDR3。
    • 8. 发明公开
    • VEGF―특이적인 인간항체
    • VEGF特异性人抗体
    • KR1020100059374A
    • 2010-06-04
    • KR1020080118124
    • 2008-11-26
    • 한국생명공학연구원
    • 박영우최소영송은정유정손명호전재원정준구장명희김성섭
    • C07K16/18C07K16/00
    • C07K16/22C07K2317/21C07K2317/622C07K2317/76
    • PURPOSE: A VEGF(vascular endothelial growth factor)-specific human antibody is provided to diagnose and treat VEGF overexpressio-related diseases. CONSTITUTION: A VEFG(vascular endothelial growth factor)-specific human antibody contains a heavy chain with a variable region(VH), or a fragment thereof; and a light chain with a variable region(VL), or a fragment thereof. The heavy chain variable region(VH) contains a heavy chain complementary determining region 1 having an amino acid sequence selected from sequences 5 to 17, HCDR 2 having an amino acid sequence selected from sequence numbers 18-30, and HCDR 3 having an amino acid sequence selected from sequence numbers 31-43. A pharmaceutical composition for preventing and treating VEGF overexpression-related diseases contains VEFG-specific human antibody.
    • 目的:提供VEGF(血管内皮生长因子)特异性人抗体来诊断和治疗VEGF过表达相关疾病。 构成:VEFG(血管内皮生长因子)特异性人抗体含有具有可变区(VH)或其片段的重链; 和具有可变区(VL)的轻链或其片段。 重链可变区(VH)包含具有选自序列5至17的氨基酸序列的重链互补决定区1,具有选自序列号18-30的氨基酸序列的HCDR 2和具有氨基酸的HCDR 3 顺序选自序列号31-43。 用于预防和治疗VEGF过表达相关疾病的药物组合物含有VEFG特异性人抗体。